Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Ophthalmology (Rochester, Minn.)

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ophtha.2015.10.034PMID 26681392PMCID PMC4766028
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.

  2015cited by this paper
• GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2015cited by this paper
• TYPE 3 NEOVASCULARIZATION: Evolution, Association With Pigment Epithelial Detachment, and Treatment Response as Revealed by Spectral Domain Optical Coherence Tomography

  2015cited by this paper
• PREVALENCE OF SUBTYPES OF RETICULAR PSEUDODRUSEN IN NEWLY DIAGNOSED EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY IN KOREAN PATIENTS

  2015cited by this paper
• Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.

  2015cited by this paper
• Environmental and genetic risk factors for retinal angiomatous proliferation

  2014cited by this paper
• The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration.

  2014cited by this paper
• Risk of scar in the comparison of age-related macular degeneration treatments trials.

  2014cited by this paper
• OPTICAL COHERENCE TOMOGRAPHY–BASED RANIBIZUMAB MONOTHERAPY FOR RETINAL ANGIOMATOUS PROLIFERATION IN KOREAN PATIENTS

  2014cited by this paper
• Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography

  2014cited by this paper
• INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL ANGIOMATOUS PROLIFERATION IN TREATMENT-NAIVE EYES: Long-term Functional and Anatomical Results Using A Modified PrONTO-Style Regimen

  2014cited by this paper
• Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials.

  2012cited by this paper
• LONG-TERM RESULTS OF INTRAVITREAL RANIBIZUMAB, INTRAVITREAL RANIBIZUMAB WITH PHOTODYNAMIC THERAPY, AND INTRAVITREAL TRIAMCINOLONE WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION

  2012cited by this paper
• Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis.

  2012cited by this paper
• Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.

  2012cited by this paper
• Reproducibility of Fluorescein and Indocyanine Green Angiographic Assessment for RAP Diagnosis: A Multicenter Study

  2012cited by this paper
• Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

  2011cited by this paper
• Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration

  2010cited by this paper
• Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation

  2009cited by this paper
• INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR RETINAL ANGIOMATOUS PROLIFERATION: Twelve-Month Results

  2009cited by this paper
• RETINAL ANGIOMATOUS PROLIFERATION: Natural History and Progression of Visual Loss

  2009cited by this paper
• Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration

  2009cited by this paper
• “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION

  2009cited by this paper
• Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration.

  2008cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION

  2007cited by this paper
• Retinal Angiomatous Proliferation Reactivation 6 Months after High-Dose Intravitreal Acetonide Triamcinolone and Photodynamic Therapy

  2007cited by this paper
• Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation.

  2005cited by this paper
• RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION

  2001cited by this paper
• Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration.

  2000cited by this paper
• Deep retinal vascular anomalous complexes in advanced age-related macular degeneration.

  1996cited by this paper
• Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments.

  1995cited by this paper

• Type 4 Macular Neovascularization (NV): A New Member of the Optical Coherence Tomography (OCT) Classification of NV Age-Related Macular Degeneration (AMD).

  2025cites this paper
• Reshaping the Burden of nAMD: National, Regional, and Global Prevalence of MNV3 and Its Correlation With Life Expectancy—The RAP Study, Report 7

  2025influential citation
• Long-term outcomes and the association between early detection of retinal pigment epithelial atrophy and remission after loading dose in eyes with retinal angiomatous proliferation

  2025cites this paper
• Ten‐Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age‐Related Macular Degeneration

  2025cites this paper
• Early prediction of macular neovascularization phenotypes and prognostic evolution

  2025cites this paper
• Progression of Loss of Vision From Centre-Involving Macular Atrophy in Eyes Treated for nAMD.

  2025cites this paper
• Long-term remission and incidence of recurrence of neovascularization in intravitreal injection treated exudative age-related macular degeneration

  2025cites this paper
• Long-term outcomes of the observe-and-plan regimen in treating neovascular age-related macular degeneration: a retrospective real-life analysis

  2025cites this paper
• Simultaneous GA and CNV/MNV: incidence, characteristics, and treatments

  2025cites this paper
• Predictors of 24-month onset of macular fibrosis in type 3 macular neovascularisation

  2024cites this paper
• Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

  2024cites this paper
• Functional and structural characteristics in patients with type 3 macular neovascularisation treated with anti-VEGF. Three-year results in real world settings

  2024cites this paper
• Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration

  2024cites this paper
• Type 3 MNV in AMD: baseline predictors of 3-year macular atrophy development.

  2024cites this paper
• Review of type 3 macular neovascularization in age-related macular degeneration: no DRAMA (Deep Retinal Age-related Microvascular Anomalies)

  2024cites this paper
• Predictors of Disease Activity After Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration Using Real-World Data from the PROOF Study

  2024cites this paper
• Quantifying Changes on OCT in Eyes Receiving Treatment for Neovascular Age-Related Macular Degeneration

  2024cites this paper
• Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes

  2024influential citation
• American Society of Retina Specialists Clinical Practice Guidelines on Multimodal Imaging for Retinal Disease

  2024cites this paper
• Long term follow up of patients with MNV3 treated with intra-vitreal Aflibercept

  2024cites this paper
• Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis

  2024cites this paper
• Retinal Angiomatous Proliferation in a Patient with Retinitis Pigmentosa

  2023influential citation
• Subretinal hyperreflective material (SHRM) in retinal and chorioretinal disorders: A comprehensive review.

  2023cites this paper
• Repurposing medications for treatment of age-related macular degeneration: Insights from novel approaches to data mining

  2023cites this paper
• Vessel density changes in choroid, chorio-capillaries, deep and superficial retinal plexues on OCTA in normal ageing and various stages of age-related macular degeneration

  2023cites this paper
• Histology of Type 3 Macular Neovascularization and Microvascular Anomalies in Treated Age-Related Macular Degeneration

  2023cites this paper
• Nascent geographic atrophy as a predictor of type 3 MNV development.

  2023cites this paper
• The Effects of Treatment Regimen on the Initial Management of Macular Neovascularization Subtypes in Age-Related Macular Degeneration

  2023cites this paper
• Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR

  2022cites this paper
• Optical coherence tomography predictors of 3-year visual outcome for type 3 macular neovascularization.

  2022cites this paper
• Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration

  2022cites this paper
• OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERIZATION OF EVOLVING LESIONS IN FELLOW EYES OF EXUDATIVE TYPE 3 MACULAR NEOVASCULARIZATION PATIENTS

  2022cites this paper
• Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?

  2022cites this paper
• Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes

  2022cites this paper
• OCT-A characterization of evolving lesions in fellow eyes of exudative type 3 MNV patients.

  2022cites this paper
• Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization

  2022cites this paper
• Characteristics That Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.

  2022cites this paper
• Three-Year Outcomes of Intravitreal Aflibercept Injections for Retinal Angiomatous Proliferation According to Disease Stage

  2022cites this paper
• Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives

  2021cites this paper
• FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR NEOVASCULARIZATION-FLIP-3 STUDY

  2021cites this paper
• OPTH_A_205147 3351..3367

  2021cites this paper
• Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization

  2021cites this paper
• Associations and outcomes of patients with submacular haemorrhage secondary to age-related macular degeneration in the IVAN trial.

  2021cites this paper
• Clinical Pathological Features and Current Animal Models of Type 3 Macular Neovascularization

  2021cites this paper
• Anti-VEGF Treatment and Optical Coherence Tomography Biomarkers in Wet Age-Related Macular Degeneration

  2021cites this paper
• Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry

  2021cites this paper
• Distinguishing retinal angiomatous proliferation from polypoidal choroidal vasculopathy with a deep neural network based on optical coherence tomography

  2021cites this paper
• Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

  2021cites this paper
• Erken ve orta evre yaşa bağlı makula dejenerasyonunun optik koherens tomografi anjografi ile değerlendirilmesi

  2020cites this paper
• Evaluating Retinal Angiomatous Proliferation With Optical Coherence Tomography Angiography.

  2020cites this paper
• Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy

  2020cites this paper
• A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II

  2020cites this paper
• Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.

  2020cites this paper
• CLINICAL OUTCOMES OF DIFFERENT SUBTYPES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DURING AFLIBERCEPT TREATMENT.

  2020cites this paper
• RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3

  2020cites this paper
• Reply.

  2020cites this paper
• Re: Nguyen et al.: Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents (Ophthalmology. 2019;126:735-742).

  2020cites this paper
• Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring

  2020cites this paper
• Optical coherence tomography angiography in type 3 neovascularization

  2020cites this paper
• Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.

  2020cites this paper
• Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.

  2020cites this paper
• Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

  2020cites this paper
• OCT Angiographic Findings in Retinal Angiomatous Proliferation OCT-angiografische Befunde bei retinalen angiomatösen Proliferationen

  2020influential citation
• Progression of macular atrophy in patients undergoing anti‐vascular endothelial growth factor therapy for neovascular age‐related macular degeneration

  2020cites this paper
• Clinical Trials Related to Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

  2020cites this paper
• Definition of Different Treatment Response Types In Neovascular Age-Related Macular Degeneration

  2020cites this paper
• Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye

  2019cites this paper
• Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation

  2019cites this paper
• Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion.

  2019cites this paper
• Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol

  2019cites this paper
• Intravitreal Aflibercept for Retinal Angiomatous Proliferation: Results of a Prospective Case Series at 96 Weeks

  2019cites this paper
• Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis

  2019cites this paper
• Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment

  2019cites this paper
• Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations

  2019influential citation
• Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation

  2019cites this paper
• Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project.

  2019cites this paper
• Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

  2019cites this paper
• Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months

  2018cites this paper
• Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

  2018cites this paper
• Choriocapillaris changes in dry age-related macular degeneration and geographic atrophy: a review

  2018cites this paper
• One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis

  2018cites this paper
• Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

  2018cites this paper
• Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

  2018cites this paper
• Type 3 neovascularisation: long-term analysis of visual acuity and optical coherence tomography anatomical outcomes

  2018cites this paper
• Precision medicine for age-related macular degeneration: current developments and prospects

  2018cites this paper
• Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture.

  2018cites this paper
• Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.

  2018cites this paper
• LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

  2017cites this paper
• Retinal angiomatous proliferation.

  2017cites this paper
• Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials.

  2017cites this paper
• It is necessary to distinguish high myopia from pathological myopia

  2017cites this paper
• Retinal Pigment Epithelial Detachment in Retinal Angiomatous Proliferation

  2017cites this paper
• Sonderformen choroidaler Neovaskularisationsmembranen

  2017influential citation
• [Choroidal Neovascularisation Other than Typical Neovascular Age-Related Macular Degeneration].

  2017cites this paper
• INCIDENCE AND CAUSES OF VISION LOSS DURING AFLIBERCEPT TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: One-Year Follow-up

  2017cites this paper
• An 8‐year follow‐up of anti‐vascular endothelial growth factor treatment with a treat‐and‐extend modality for neovascular age‐related macular degeneration

  2017cites this paper
• RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINAL ANGIOMATOUS PROLIFERATION

  2017cites this paper
• Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy

  2017cites this paper
• INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION

  2017cites this paper
• Geographic atrophy phenotype identification by cluster analysis

  2017cites this paper